1
Eric First, M.D.
First Eric R, Irvine Ryan A: Methods for enhancing therapeutic effects of a neurotoxin. Allergan, First Eric R, Irvine Ryan A, NASSIF Claude, August 2, 2007: WO/2007/087154 (3 worldwide citation)

The present invention relates to methods for enhancing the therapeutic effects of a neurotoxin, e.g., a botulinum toxin, where the methods comprise a 'wash-down' (e.g., a decreased intake) of a current pain medication and an administration of a neurotoxin. In some embodiments, the present inventions ...


2
Yu Ruey J Dr, Van Scott Eugene J Dr: Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use.. Yu Ruey J, Scott Eugene J Van, February 20, 1991: EP0413528-A1 (162 worldwide citation)

Preventive as well as therapeutic treatment to alleviate cosmetic conditions and symptoms of dermatologic disorders with amphoteric compositions containing alpha hydroxyacids, alpha ketoacids, related compounds or polymeric forms of hydroxyacids is disclosed. The cosmetic conditions and the dermatol ...


3
Burt Helen M, Hunter William L, Machan Lindsay S, Arsenault A Larry, Jackson John K: Anti-angiogenic compositions and methods of use. Angiogenesis Tech, Univ British Columbia, April 17, 1996: EP0706376-A1 (129 worldwide citation)

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and e ...


4
Della Valle Francesco, Romeo Aurelio, Lorenzi Silvana: Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same.. Fidia, April 24, 1985: EP0138572-A2 (128 worldwide citation)

Two pharmaceutically useful fractions of hyaluronic acid are obtained comprising a first fraction with a molecular weight between 50,000 and 100,000 which is useful for wound healing, and a second fraction having a molecular weight between 500,000 and 730,000 which is useful for intraocular and intr ...


5
Higuchi Takeru, Nishihata Toshiaki: An orally administered drug form comprising a polar bioactive agent and an adjuvant.. Interx Research, September 23, 1981: EP0036145-A1 (117 worldwide citation)

A drug form is provided for increasing the oral absorption of polar bioactive agents such as xanthines, polyhydroxylic substances, zwitterions, polypeptides and organic anions and related chemical species by the oral administration of said polar bioactive agents in a suitable pharmaceutically accept ...


6
Della Valle Francesco, Romeo Aurelio, Lorenzi Silvana: New medicaments for topical use.. Fidia, October 15, 1986: EP0197718-A2 (93 worldwide citation)

Pharmaceutical preparations for non-topical administration containing a pharmacologically active substance together with hyaluronic acid or a molecular weight fraction thereof. The hyaluronic acid may be in the form of the free acid or may be a salt with an alkali or alkaline earth metal, magnesium, ...


7

8
Sommadossi Jean Pierre, La, Colla Paolo, Standring David, Bichko Vadim, Qu Lin: 2’-branched nucleosides and flaviviridae mutation. Idenix, Universita Degli Studi Di Cagliari, Sommadossi Jean Pierre, La, Colla Paolo, Standring David, Bichko Vadim, Qu Lin, KNOWLES Sherry M, June 3, 2004: WO/2004/046331 (82 worldwide citation)

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2'-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or in ...


9
Burt Helen M, Jackson John K, Hunter William L, Machan Lindsay S, Arsenault Larry A: Anti-angiogenic compositions and methods of use. Angiotech Pharm, Univ British Columbia, October 1, 1997: EP0797988-A2 (82 worldwide citation)

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and e ...


10
Raffa Robert B: Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug.. Mcneilab, June 16, 1993: EP0546676-A1 (81 worldwide citation)

This invention relates to a composition comprising a tramadol material and a nonsteroidal antiinflammatory drug, and its use. The compositions are pharmacologically useful in treating pain and tussive conditions. The compositions are also subject to less opioid side-effects such as abuse liability, ...